{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:54:28Z","timestamp":1780437268890,"version":"3.54.1"},"reference-count":26,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2022]]},"DOI":"10.3960\/jslrt.21031","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T22:09:44Z","timestamp":1644617384000},"page":"91-98","source":"Crossref","is-referenced-by-count":5,"title":["Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy"],"prefix":"10.3960","volume":"62","author":[{"given":"Manabu","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Hematology, Fukushima Medical University Aizu Medical Center, Aizuwakamatsu, Fukushima, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University Aizu Medical Center, Aizuwakamatsu, Fukushima, Japan,"},{"name":"Department of Hematology, Fukushima Medical University, Hikarigaoka, Fukushima, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University Aizu Medical Center, Aizuwakamatsu, Fukushima, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masumi","family":"Sukegawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University Aizu Medical Center, Aizuwakamatsu, Fukushima, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Teshirogi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University Aizu Medical Center, Aizuwakamatsu, Fukushima, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Misawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Shizuoka Hospital, Izunokuni, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saburo","family":"Tsunoda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University Aizu Medical Center, Aizuwakamatsu, Fukushima, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009; 27: 1492-1501.","DOI":"10.1200\/JCO.2008.18.7252"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016; 57: 512-519.","DOI":"10.3109\/10428194.2015.1110748"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Gordon MJ, Lewis LD, Brown JR, Danilov AV. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities \u2013 is there an optimal dose? Expert Rev Hematol. 2017; 10: 707-718.","DOI":"10.1080\/17474086.2017.1350166"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Bogelji\u0107 Patekar M, Milunovi\u0107 V, Mi\u0161ura Jakobac K <i>et al.<\/i> Bendamustine: an old drug in the new era for patients with non-Hodgkin lymphomas and chronic lymphocytic leukemia. Acta Clin Croat. 2018; 57: 542-553.","DOI":"10.20471\/acc.2018.57.03.18"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Hiraoka N, Kikuchi J, Koyama D <i>et al.<\/i> Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma. Blood Cancer J. 2013; 3: e169.","DOI":"10.1038\/bcj.2013.66"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Hiraoka N, Kikuchi J, Yamauchi T <i>et al.<\/i> Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies. PLoS One. 2014; 9: e90675.","DOI":"10.1371\/journal.pone.0090675"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Rummel MJ, Niederle N, Maschmeyer G <i>et al.<\/i> Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381: 1203-1210.","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ito K, Okamoto M, Ando M <i>et al.<\/i> Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2015; 56: 1123-1125.","DOI":"10.3109\/10428194.2014.921298"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Hosoda T, Yokoyama A, Yoneda M <i>et al.<\/i> Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma. 2013; 54: 1327-1328.","DOI":"10.3109\/10428194.2012.739285"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Nishikori M, Kitano T, Kobayashi M <i>et al.<\/i> Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine. Int J Hematol. 2015; 102: 53-58.","DOI":"10.1007\/s12185-015-1791-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Uchida M, Kawashiri T, Maegawa N <i>et al.<\/i> Pharmacovigilance evaluation of bendamustine-related skin disorders using the Japanese adverse drug event report database. J Pharm Pharm Sci. 2021; 24: 16-22.","DOI":"10.18433\/jpps31597"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Matthews SN, Cockerell CJ. Prurigo nodularis in HIV-infected individuals. Int J Dermatol. 1998; 37: 401-409.","DOI":"10.1046\/j.1365-4362.1998.00507.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Cheson BD, Pfistner B, Juweid ME <i>et al.<\/i> Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586.","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013; 48: 452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Koyama D, Sato Y, Aizawa M <i>et al.<\/i> Soluble \u03b1Klotho as a candidate for the biomarker of aging. Biochem Biophys Res Commun. 2015; 467: 1019-1025.","DOI":"10.1016\/j.bbrc.2015.10.018"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Yamamoto S, Koyama D, Igarashi R <i>et al.<\/i> Serum endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease and various metabolic dysfunctions in aged patients. Intern Med. 2020; 59: 345-355.","DOI":"10.2169\/internalmedicine.3597-19"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Suzuki M, Tsunoda S, Koyama D <i>et al.<\/i> MTX-HOPE is a low-dose salvage chemotherapy for aged patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Exp Hematop. 2021; 61: 22-28.","DOI":"10.3960\/jslrt.20051"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Ikeda S, Tsunoda S, Koyama D <i>et al.<\/i> Femoral marrow MRI is a non-invasive, non-irradiated and useful tool for detecting bone marrow involvement in non-Hodgkin lymphoma. J Clin Exp Hematop. 2021; 61: 78-84.","DOI":"10.3960\/jslrt.20054"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Flinn IW, van der Jagt R, Kahl BS <i>et al.<\/i> Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014; 123: 2944-2952.","DOI":"10.1182\/blood-2013-11-531327"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Gafter-Gvili A, Ribakovsky E, Mizrahi N <i>et al.<\/i> Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. Leuk Lymphoma. 2016; 57: 63-69.","DOI":"10.3109\/10428194.2015.1046862"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Herold M, Schulze A, Niederwieser D <i>et al.<\/i> Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol. 2006; 132: 105-112.","DOI":"10.1007\/s00432-005-0023-2"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Garc\u00eda Mu\u00f1oz R, Izquierdo-Gil A, Mu\u00f1oz A <i>et al.<\/i> Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol. 2014; 93: 1879-1887.","DOI":"10.1007\/s00277-014-2135-8"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Yutaka T, Ito S, Ohigashi H <i>et al.<\/i> Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma. Leuk Lymphoma. 2015; 56: 3216-3218.","DOI":"10.3109\/10428194.2015.1026818"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Wakeel RA, Urbaniak SJ, Armstrong SS <i>et al.<\/i> Idiopathic CD4+ lymphocytopenia associated with chronic pruritic papules. Br J Dermatol. 1994; 131: 371-375.","DOI":"10.1111\/j.1365-2133.1994.tb08527.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Aggarwal M, Rein J. Acute human immunodeficiency virus syndrome in an adolescent. Pediatrics. 2003; 112: e323.","DOI":"10.1542\/peds.112.4.e323"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Kobayashi S, Segawa S, Kawashima M <i>et al.<\/i> A case of symptomatic primary HIV infection. J Dermatol. 2005; 32: 137-142.","DOI":"10.1111\/j.1346-8138.2005.tb00732.x"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/2\/62_21031\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:42:52Z","timestamp":1715233372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/2\/62_21031\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.21031","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"21031"}}